Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Distinct Chromatin Accessibility Changes, Aberrant Transcription Factor Networks Combined with Novel Oncogenic Enhancers Characterise Myeloma-Initiating Genetic Events

Nikolaos Trasanidis, Jaime Alvarez-Benayas, Alexia Katsarou, Aristeidis Chaidos, Philippa C May, Kanagaraju Ponnusamy, Xiaolin Xiao, Marco Bua, MD, Maria Atta, MD, Irene Roberts, Holger W Auner, MD PhD, Evdoxia Hatjiharissi, Maria Papaioannou, Valentina S Caputo, Ian Sudbery, Anastasios Karadimitris

Blood (2019) 134 (Supplement_1): 1769.

https://doi.org/10.1182/blood-2019-124761

Published: 2019

Journal Articles

Clustering Analysis of Myeloma Clone Phenotype Is Informative for Disease Heterogeneity and Prognosis at Relapse

Syeda Maheen Ahsan, Elisabet Nadal-Melsio, MD, Mark E Robinson, PhD, Richard Syzdlo, PhD, Eva Yebra-Fernandez, MD, Holger W Auner, MD PhD, Maria Atta, MD, Marco Bua, MD, Farah O'Boyle, PhD, Kikkeri Naresh, Jane Apperley, MB ChB MD, Anastasios Karadimitris, FRCPath, PhD, Aristeidis Chaidos, MD PhD

Blood (2018) 132 (Supplement 1): 4492.

https://doi.org/10.1182/blood-2018-99-117460

Published: 2018

Journal Articles

Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib

Dragana Milojkovic, MD, Amr R Ibrahim, Letizia Foroni, MD PhD, Claire Lucas, Gareth Gerrard, PhD, Lihui Wang, Richard M Szydlo, Richard E Clark, Jane F Apperley, MBChB, MD, FRCP, FRCPath, Marco Bua, MD, Jiri Pavlu, Christos Paliompeis, Alistair Reid, PhD, Katy Rezvani, MBBS, PhD, MRCP, FRCPath, John M Goldman, David Marin

Blood (2011) 118 (21): 1680.

https://doi.org/10.1182/blood.V118.21.1680.1680

Published: 2011

Journal Articles

The Natural History of RTQ-PCR Levels After the Achievement of Complete Molecular Remission (CMR): Implications for ‘Stopping' Studies

Dragana Milojkovic, MD, Gareth Gerrard, PhD, Christos Paliompeis, Marco Bua, MD, Alistair Reid, PhD, Mary Alikian, Jamshid Khorashad, MD, PhD, John M Goldman, David Marin, Letizia Foroni, MD PhD, Jane F Apperley, MBChB, MD, FRCP, FRCPath

Blood (2011) 118 (21): 605.

https://doi.org/10.1182/blood.V118.21.605.605

Published: 2011

Journal Articles

Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor Have Normal T Cell Responses to Vaccination but An Impaired IgM Humoral Response Associated with Loss of Discrete Memory B Cell Subsets,

Blood (2011) 118 (21): 3753.

https://doi.org/10.1182/blood.V118.21.3753.3753

Published: 2011

Journal Articles

Prolonged Survival Following Imatinib Failure for CML Patients in CP May Require Multiple TKI Strategies for Responding Patients,

Dragana Milojkovic, MD, Jane F Apperley, MBChB, MD, FRCP, FRCPath, Amr R Ibrahim, Marco Bua, MD, Alistair Reid, PhD, Gareth Gerrard, PhD, Letizia Foroni, MD PhD, Katy Rezvani, MBBS, PhD, MRCP, FRCPath, John M Goldman, David Marin

Blood (2011) 118 (21): 3777.

https://doi.org/10.1182/blood.V118.21.3777.3777

Published: 2011

Journal Articles

T-Cell and B-Cell Responses After Vaccination against Influenza Virus and Pneumococcus in Chronic Phase CML Patients Treated with Tyrosine Kinase Inhibitors.

Hugues de Lavallade, MD, MsC, Melanie Hart, PhD, Ian H Gabriel, Dr, Peter Kelleher, MD, PhD, Abdullah Alsuliman, PhD, Ahmad Khoder, MD, Dragana Milojkovic, MD, Letizia Foroni, Marco Bua, MD, Jane F. Apperley, MBChB, FRCP, FRCPath, John M Goldman, DM, FCRP, David Marin, MD, Katayoun Rezvani, MD, PhD

Blood (2009) 114 (22): 2214.

https://doi.org/10.1182/blood.V114.22.2214.2214

Published: 2009

Journal Articles

Long Term Durability of Major Molecular Responses for Patients Treated with Imatinib after Failure of Interferon-Alfa Is Equivalent to That of Patients Achieving Major Molecular Responses to Imatinib as Primary Therapy.

Hugues de Lavallade, MD, Jamshid S. Khorashad, MD, Marco Bua, MD, Dragana Milojkovic, MD, Eduardo Olavarria, MD, Alistair Reid, PhD, Jaspal S. Kaeda, PhD, John M. Goldman, DM, Jane F. Apperley, MD, David Marin, MD

Blood (2007) 110 (11): 1037.

https://doi.org/10.1182/blood.V110.11.1037.1037

Published: 2007

Journal Articles

Homoharringtonine in Combination with Imatinib for Patients with CML Who Have Achieved Partial or Complete Cytogenetic Responses.

Rifca Le Dieu, MD, Marco Bua, MD, Catharina Andreasson, Eduardo Olavarria, MD, Jonh M. Goldman, DM, Jane F. Apperley, MD, David Marin, MD

Blood (2004) 104 (11): 1012.

https://doi.org/10.1182/blood.V104.11.1012.1012

Published: 2004

NARROW

Distinct Chromatin Accessibility Changes, Aberrant Transcription Factor Networks Combined with Novel Oncogenic Enhancers Characterise Myeloma-Initiating Genetic Events

Clustering Analysis of Myeloma Clone Phenotype Is Informative for Disease Heterogeneity and Prognosis at Relapse

Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib

The Natural History of RTQ-PCR Levels After the Achievement of Complete Molecular Remission (CMR): Implications for ‘Stopping' Studies

Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor Have Normal T Cell Responses to Vaccination but An Impaired IgM Humoral Response Associated with Loss of Discrete Memory B Cell Subsets,

Prolonged Survival Following Imatinib Failure for CML Patients in CP May Require Multiple TKI Strategies for Responding Patients,

T-Cell and B-Cell Responses After Vaccination against Influenza Virus and Pneumococcus in Chronic Phase CML Patients Treated with Tyrosine Kinase Inhibitors.

Long Term Durability of Major Molecular Responses for Patients Treated with Imatinib after Failure of Interferon-Alfa Is Equivalent to That of Patients Achieving Major Molecular Responses to Imatinib as Primary Therapy.

Homoharringtonine in Combination with Imatinib for Patients with CML Who Have Achieved Partial or Complete Cytogenetic Responses.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only